Show simple item record

dc.contributor.authorKyrgiou, M.en
dc.contributor.authorSalanti, G.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorParaskevaidis, E.en
dc.contributor.authorIoannidis, J. P. A.en
dc.creatorKyrgiou, M.en
dc.creatorSalanti, G.en
dc.creatorPavlidis, Nicholasen
dc.creatorParaskevaidis, E.en
dc.creatorIoannidis, J. P. A.en
dc.date.accessioned2018-06-22T09:53:52Z
dc.date.available2018-06-22T09:53:52Z
dc.date.issued2006
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42062
dc.description.abstractBackground: Numerous randomized trials have compared different chemotherapy regimens in women with ovarian cancer. Although ovarian cancer survival has improved in recent years, the magnitude of these incremental benefits across diverse regimens is unclear. Methods: We used multiple-treatment meta-analysis methodology to combine information from direct and indirect comparisons of all chemotherapy regimens used in randomized trials of ovarian cancer in the last 40 years. Chemotherapy was categorized by the use or not of platinum and/or taxanes, combinations of agents, and intraperitoneal administration. Monte Carlo simulations were used to determine which regimen most improved survival. Analyses of trials that examined first- and second-line treatments were also performed separately. Results: We found 198 trials (N = 38 440 women) involving 120 different chemotherapy regimens published in 1971=2006. Eighty-two trials compared different types of chemotherapy, among which 60 had usable survival information (N = 15 609 women). Monte Carlo simulations showed a 92% probability that the regimen that best prolonged survival is a platinum and taxane combination with intraperitoneal administration; this regimen resulted in a 55% relative risk reduction (95% confidence interval [CI] = 39% to 67%) for mortality as compared with nonintraperitoneal monotherapy using neither platinum nor taxane. Against that same monotherapy comparator, platinum-based combinations with and without intraperitoneal administration achieved 40% (95% CI = 21% to 54%) and 30% (95% CI = 20% to 38%) relative risk reductions for mortality, respectively, and combinations involving platinum and taxane without intraperitoneal administration achieved a 42% (95% CI = 31% to 51%) relative risk reduction. Results were similar when analyses were limited to first-line treatment. Data on second-line treatment were consistent with the superiority of platinum and taxane combinations. Conclusions: Distinct incremental improvements in survival have been achieved for ovarian cancer chemotherapy over time, with the possibility to achieve a doubling or more of time to mortality with platinum and taxane combinations, especially when intraperitoneal administration is used. © 2006 Oxford University Press.en
dc.language.isoengen
dc.sourceJournal of the National Cancer Instituteen
dc.subjectMethodologyen
dc.subjectArticleen
dc.subjectAntineoplastic agenten
dc.subjectAntineoplastic agentsen
dc.subjectBleomycinen
dc.subjectCisplatinen
dc.subjectCyclophosphamideen
dc.subjectDactinomycinen
dc.subjectDoxorubicinen
dc.subjectEtoposideen
dc.subjectHumanen
dc.subjectVincristineen
dc.subjectHumansen
dc.subjectFemaleen
dc.subjectInformationen
dc.subjectCancer combination chemotherapyen
dc.subjectCancer survivalen
dc.subjectCarboplatinen
dc.subjectOvarian neoplasmsen
dc.subjectOvary canceren
dc.subjectPaclitaxelen
dc.subjectPriority journalen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectClinical trialen
dc.subjectGemcitabineen
dc.subjectMonotherapyen
dc.subjectOxaliplatinen
dc.subjectTaxane derivativeen
dc.subjectTaxoidsen
dc.subjectTopotecanen
dc.subjectInfusionsen
dc.subjectSurvival analysisen
dc.subjectCancer mortalityen
dc.subjectRisk reductionen
dc.subjectConfidence intervalen
dc.subjectBusulfanen
dc.subjectMelphalanen
dc.subjectSystematic reviewen
dc.subjectEpirubicinen
dc.subjectPlatinum complexen
dc.subjectMeta analysisen
dc.subjectStatistical analysisen
dc.subjectOrganoplatinum compoundsen
dc.subjectRandomized controlled trialsen
dc.subjectSurvival timeen
dc.subjectIfosfamideen
dc.subjectAltretamineen
dc.subjectChlorambucilen
dc.subjectMonte carlo methoden
dc.subjectThiotepaen
dc.subjectParenteralen
dc.subjectPrednimustineen
dc.subjectProbabilityen
dc.subjectThiosulfateen
dc.subjectTreosulfanen
dc.titleSurvival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatmentsen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1093/jnci/djj443
dc.description.volume98
dc.description.issue22
dc.description.startingpage1655
dc.description.endingpage1663
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record